Skip to content

Evaluation of Prokineticin-2 as a Diagnostic Marker of Sepsis: A Comparative Study with Procalcitonin and Blood Culture

Diagnostic validity of Prokineticin-2 compared to Procalcitonin and Blood culture in patients with sepsis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/093997
Enrollment
160
Registered
2025-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R798- Other specified abnormal findingsof blood chemistry

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Jawaharlal Nehru Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients with suspected of sepsis in IPD patients 2 Before antibiotic initiation, sample sent for Aerobic Bacterial Blood culture and Procalcitonin for the same patient 3 Estimation of Prokineticin-2 within 1 hour to prevent variability 4 Age 18 years or more

Exclusion criteria

Exclusion criteria: 1.Prior antibiotic therapy more than 24 hours before sample collection 2. Either of Blood culture or Procalcitonin investigation not advised 3. Negative Blood culture reported are excluded 4. Procalcitonin level less than or equal to cut off value 0.5ng/ml are excluded 5. Patients with autoimmune diseases, HIV, HBsAg, HCV are excluded. 6. Patients on long term steroids immunosuppressants chemotherapy or with terminal illness malignant cancer end-stage liver or renal disease are excluded

Design outcomes

Primary

MeasureTime frame
Prokineticin-2 can be useful marker to diagnose sepsis effectivelyTimepoint: 1 year

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactOjas Kumar Aggarwal

Jawaharlal Nehru Medical College

naragundsmita@gmail.com9901662601

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026